Literature DB >> 14999658

Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach.

Cornelis C Kan1, Sander R Hilberink, Marinus H M Breteler.   

Abstract

The aim of this study was to identify risk factors for benzodiazepine (BZD) dependence, such as sociodemographic variables, characteristics of BZD use, and psychiatric parameters, which to date have been found to relate inconsistently to indicators of BZD dependence such as chronic BZD use and BZD withdrawal symptoms. The Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ), Schedules for Clinical Assessment in Neuropsychiatry (SCAN), and Symptom Checklist-90 (SCL-90) were administered to 599 outpatients using BZDs. Regression analyses were conducted using BZD dependence diagnoses and severity scales as dependent variables. BZD dependence diagnoses were only predicted by being a self-help patient and long BZD elimination half-life (for only the DSM-III-R). The main predictors of BZD dependence severity, as measured by the ICD-10, DSM-III-R scales, and Bendep-SRQ Rasch scales, were in decreasing order: (1) being a self-help patient; (2) higher BZD dose, longer duration of BZD use, younger age; and (3) non-native cultural origin, lower level of education, being in outpatient treatment for alcohol and/or drug dependence, and the interaction of BZD dose with duration of BZD use. We conclude that a limited number of recognizable risk factors appear to predict the severity of BZD dependence. Additional administration of a specific BZD dependence instrument is recommended to confirm suspected BZD dependence and guide further clinical decision-making.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999658     DOI: 10.1016/j.comppsych.2003.12.007

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  10 in total

1.  Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; S Randall; E Harris; R Maan; T Roth
Journal:  J Psychopharmacol       Date:  2011-10-16       Impact factor: 4.153

2.  Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; Surilla Randall; Erica Harris; Renee Maan; Thomas Roth
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

Review 3.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

Review 4.  Tolerance to allopregnanolone with focus on the GABA-A receptor.

Authors:  Sahruh Turkmen; Torbjorn Backstrom; Goran Wahlstrom; Lotta Andreen; Inga-Maj Johansson
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

Review 5.  Illicit and nonmedical drug use among older adults: a review.

Authors:  Li-Tzy Wu; Dan G Blazer
Journal:  J Aging Health       Date:  2010-11-17

6.  Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids.

Authors:  Di Liang; Yuyan Shi
Journal:  Drug Alcohol Rev       Date:  2019-07

7.  Cognitive Expectancies for Hypnotic Use among Older Adult Veterans with Chronic Insomnia.

Authors:  Constance H Fung; Jennifer L Martin; Karen Josephson; Lavinia Fiorentino; Joseph M Dzierzewski; Stella Jouldjian; Yeonsu Song; Juan Carlos Rodriguez Tapia; Michael N Mitchell; Cathy A Alessi
Journal:  Clin Gerontol       Date:  2017-09-29       Impact factor: 2.619

8.  Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees.

Authors:  Di Liang; Huiying Guo; Yuyan Shi
Journal:  Subst Abus       Date:  2019-11-07       Impact factor: 3.716

9.  Current state of hypnotic use disorders: Results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire.

Authors:  Mai Yamamoto; Ken Inada; Minori Enomoto; Mitsunari Habukawa; Takahisa Hirose; Yuichi Inoue; Jun Ishigooka; Yuichi Kamei; Tsuyoshi Kitajima; Masayuki Miyamoto; Hideto Shinno; Katsuji Nishimura; Motohiro Ozone; Masahiro Takeshima; Mayumi Suzuki; Hidehisa Yamashita; Kazuo Mishima
Journal:  Neuropsychopharmacol Rep       Date:  2020-12-01

10.  Potentially inappropriate use of benzodiazepines and z-drugs in the older population-analysis of associations between long-term use and patient-related factors.

Authors:  Aliaksandra Mokhar; Niklas Tillenburg; Jörg Dirmaier; Silke Kuhn; Martin Härter; Uwe Verthein
Journal:  PeerJ       Date:  2018-05-22       Impact factor: 2.984

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.